Table 3.
Four-year rates for DFS, DDFS, and OS in subgroups by biological subtype.
| HER2-/HR + | TNBC | HER2 + /HR + | HER2 + /HR- | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Subgroups | DFS rate (95% CI) | DDFS rate (95% CI) | OS rate (95% CI) | DFS rate (95% CI) | DDFS rate (95% CI) | OS rate (95% CI) | DFS rate (95% CI) | DDFS rate (95% CI) | OS rate (95% CI) | DFS rate (95% CI) | DDFS rate (95% CI) | OS rate (95% CI) |
| cT1 |
92.7% (83.4%, 96.9%) |
95.6% (86.9%, 98.6%) |
98.6% (90.4%, 99.8%) |
87.8% (81.7%, 92.0%) |
91.1% (85.6%, 94.5%) |
93.8% (88.8%, 96.6%) |
92.3% (84.6%, 96.3%) |
94.5% (87.2%, 97.7%) |
96.7% (90.3%, 98.9%) |
97.0% (88.4%, 99.2%) |
98.5% (89.6%, 99.8%) |
98.4% (89.4%, 99.8%) |
| cT2 |
91.6% (87.3%, 94.5%) |
94.6% (90.9%, 96.8%) |
97.1% (94.0%, 98.6%) |
91.3% (88.4%, 93.6%) |
94.2% (91.6%, 96.0%) |
95.6% (93.3%, 97.2%) |
88.5% (83.1%, 92.2%) |
91.5% (86.7%, 94.7%) |
96.8% (92.9%, 98.5%) |
89.7% (84.2%, 93.4%) |
93.2% (88.4%, 96.1%) |
96.6% (92.5%, 98.4%) |
| cT3/4 |
92.1% (82.0%, 96.6%) |
93.8% (84.3%, 97.6%) |
95.3% (86.0%, 98.4%) |
88.7% (80.6%, 93.6%) |
89.7% (81.6%, 94.3%) |
90.6% (82.7%, 95.0%) |
85.8% (75.2%, 92.1%) |
87.2% (76.8%, 93.1%) |
96.9% (88.0%, 99.2%) |
79.3% (70.2%, 85.9%) |
83.2% (74.5%, 89.1%) |
87.6% (79.6%, 92.6%) |
| cN0 |
93.9% (89.5%, 96.5%) |
95.9% (92.0%, 97.9%) |
99.0% (96.0%, 99.7%) |
93.3% (90.4%, 95.3%) |
96.1% (93.8%, 97.6%) |
96.7% (94.6%, 98.1%) |
92.9% (88.2%, 95.7%) |
96.1% (92.3%, 98.0%) |
97.5% (94.2%, 99.0%) |
88.4% (82.2%, 92.6%) |
91.0% (85.2%, 94.6%) |
95.6% (91.1%, 97.9%) |
| cN+ |
89.5% (83.8%, 93.3%) |
93.1% (88.1%, 96.0%) |
94.7% (90.1%, 97.2%) |
85.6% (81.0%, 89.2%) |
88.0% (83.6%, 91.3%) |
91.5% (87.5%, 94.2%) |
84.5% (77.9%, 89.3%) |
86.1% (79.6%, 90.7%) |
95.7% (90.7%, 98.1%) |
87.4% (81.8%, 91.4%) |
91.3% (86.3%, 94.5%) |
93.0% (88.3%, 95.9%) |
| Lobular tumor type |
83.6% (64.9%, 92.8%) |
87.1% (69.1%, 94.9%) |
93.5% (76.5%, 98.3%) |
70.1% (42.3%, 86.3%) |
82.4% (54.7%, 93.9%) |
82.4% (54.7%, 93.9%) |
100% (100%, 100%) |
100% (100%, 100%) |
100% (100%, 100%) |
87.5% (38.7%, 98.1%) |
87.5% (38.7%, 98.1%) |
87.5% (38.7%, 98.1%) |
| Non-lobular tumor type |
92.7% (89.3%, 95.0%) |
95.3% (92.5%, 97.1%) |
97.3% (94.9%, 98.6%) |
90.7% (88.3%, 92.6%) |
93.1% (91.0%, 94.8%) |
94.8% (92.9%, 96.3%) |
88.8% (85.0%, 91.6%) |
91.3% (87.8%, 93.8%) |
96.7% (94.1%, 98.2%) |
87.9% (83.9%, 91.0%) |
91.2% (87.7%, 93.8%) |
94.4% (91.3%, 96.4%) |
| Ki-67 ≤ 20% |
92.0% (80.0%, 96.9%) |
96.0% (84.9%, 99.0%) |
98.0% (86.6%, 99.7%) |
90.9% (68.1%, 97.7%) |
90.9% (68.1%, 97.7%) |
96.0% (74.8%, 99.4%) |
87.8% (78.4%, 93.3%) |
89.4% (80.5%, 94.3%) |
97.6% (90.8%, 99.4%) |
90.5% (80.0%, 95.6%) |
92.2% (82.1%, 96.7%) |
94.0% (84.7%, 97.7%) |
| Ki-67 > 20% |
91.3% (85.5%, 94.9%) |
92.0% (86.3%, 95.4%) |
95.1% (89.9%, 97.6%) |
90.3% (86.9%, 92.8%) |
93.8% (90.9%, 95.8%) |
95.7% (93.1%, 97.3%) |
90.8% (85.8%, 94.1%) |
94.4% (90.0%, 96.8%) |
97.4% (93.8%, 98.9%) |
86.7% (80.6%, 91.0%) |
90.3% (84.8%, 93.8%) |
93.6% (88.8%, 96.4%) |
| Grade 1/2 |
90.8% (85.6%, 94.2%) |
94.1% (89.6%, 96.7%) |
97.3% (93.7%, 98.9%) |
87.1% (80.9%, 91.4%) |
89.7% (83.9%, 93.5%) |
92.5% (87.1%, 95.7%) |
87.0% (81.3%, 91.1%) |
89.6% (84.2%, 93.3%) |
96.5% (92.4%, 98.4%) |
87.0% (80.1%, 91.6%) |
90.6% (84.3%, 94.4%) |
94.1% (88.5%, 97.0%) |
| Grade 3 |
93.2% (88.4%, 96.1%) |
94.9% (90.4%, 97.3%) |
96.5% (92.3%, 98.4%) |
91.2% (88.5%, 93.3%) |
93.8% (91.4%, 95.5%) |
95.1% (92.9%, 96.7%) |
90.5% (85.0%, 94.1%) |
93.0% (88.0%, 96.0%) |
97.0% (92.8%, 98.7%) |
88.4% (83.2%, 92.1%) |
91.4% (86.7%, 94.5%) |
94.3% (90.1%, 96.7%) |
| Age ≤ 40 years |
94.6% (87.6%, 97.7%) |
96.7% (90.2%, 98.9%) |
98.9% (92.7%, 99.8%) |
90.1% (84.9%, 93.6%) |
92.8% (88.2%, 95.7%) |
94.8% (90.6%, 97.2%) |
91.0% (80.9%, 95.9%) |
95.4% (86.3%, 98.5%) |
98.2% (87.8%, 99.7%) |
88.3% (77.0%, 94.3%) |
93.2% (82.9%, 97.4%) |
94.9% (84.9%, 98.3%) |
| Age 41–59 years |
89.9% (85.1%, 93.1%) |
93.1% (88.9%, 95.7%) |
96.0% (92.5%, 97.9%) |
90.8% (87.6%, 93.1%) |
93.1% (90.2%, 95.1%) |
94.6% (92.0%, 96.4%) |
88.0% (83.0%, 91.6%) |
90.7% (86.1%, 93.9%) |
97.2% (93.9%, 98.8%) |
86.9% (81.5%, 90.7%) |
90.8% (86.0%, 93.9%) |
94.3% (90.2%, 96.7%) |
| Age ≥ 60 years |
96.1% (85.2%, 99.0%) |
98.0% (86.9%, 99.7%) |
98.0% (86.9%, 99.7%) |
88.4% (80.4%, 93.2%) |
92.3% (85.1%, 96.1%) |
94.1% (87.2%, 97.3%) |
89.8% (79.6%, 95.0%) |
89.8% (79.6%, 95.0%) |
94.0% (84.7%, 97.7%) |
90.6% (81.3%, 95.4%) |
90.6% (81.3%, 95.4%) |
93.3% (84.8%, 97.2%) |
| Premenopausal |
92.6% (88.4%, 95.4%) |
95.2% (91.5%, 97.3%) |
97.8% (94.9%, 99.1%) |
89.6% (86.3%, 92.1%) |
92.6% (89.8%, 94.7%) |
94.7% (92.2%, 96.5%) |
89.0% (84.1%, 92.5%) |
92.7% (88.3%, 95.5%) |
97.0% (93.4%, 98.7%) |
84.4% (78.3%, 88.9%) |
89.9% (84.5%, 93.4%) |
94.0% (89.3%, 96.6%) |
| Postmenopausal |
90.7% (84.5%, 94.5%) |
93.8% (88.3%, 96.7%) |
95.7% (90.6%, 98.0%) |
91.1% (87.1%, 93.9%) |
93.2% (89.5%, 95.6%) |
94.2% (90.7%, 96.4%) |
88.8% (82.3%, 93.0%) |
89.5% (83.2%, 93.5%) |
96.4% (91.5%, 98.5%) |
91.9% (86.4%, 95.2%) |
92.5% (87.2%, 95.7%) |
94.4% (89.5%, 97.0%) |
| ypT0 |
91.7% (87.8%, 94.4%) |
94.7% (91.3%, 96.8%) |
97.2% (94.4%, 98.6%) |
91.1% (88.6%, 93.1%) |
93.2% (91.0%, 94.9%) |
95.0% (93.0%, 96.4%) |
91.0% (87.0%, 93.9%) |
92.7% (88.9%, 95.2%) |
96.6% (93.5%, 98.2%) |
90.6% (86.4%, 93.5%) |
92.1% (88.1%, 94.8%) |
94.6% (91.1%, 96.8%) |
| ypTis |
92.4% (84.7%, 96.3%) |
94.6% (87.5%, 97.7%) |
96.7% (90.0%, 98.9%) |
83.8% (74.2%, 90.1%) |
90.6% (82.1%, 95.2%) |
91.6% (83.0%, 95.9%) |
82.0% (71.9%, 88.8%) |
87.0% (77.8%, 92.6%) |
97.4% (90.1%, 99.4%) |
79.7% (69.2%, 86.9%) |
88.2% (79.1%, 93.5%) |
93.1% (85.4%, 96.9%) |
BMI body mass index, DDFS distant disease-free survival, DFS disease-free survival, ER estrogen receptor, PgR progesterone receptor, HER2 human epidermal growth factor receptor 2, HR hormone receptor, OS overall survival, TNBC triple-negative breast cancer